Ikarian Capital, LLC Immatics N.V. Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.23 - $12.94 $3,928 - $4,968	384 Added 0.78%	49,415 $519,000
Q2 2023 Aug 14, 2023	SELL	$5.92 - $12.72 $772,684 - $1.66 Million	-130,521 Reduced 72.69%	49,031 $565,000
Q1 2023 May 15, 2023	BUY	$6.74 - $9.44 $879,711 - $1.23 Million	130,521 Added 266.2%	179,552 $1.24 Million
Q3 2022 Nov 14, 2022	SELL	$3.31 - $13.06 $358,006 - $1.41 Million	-108,159 Reduced 68.81%	49,031 $490,000
Q2 2022 Aug 12, 2022	SELL	$6.0 - $9.37 $3.75 Million - $5.85 Million	-624,198 Reduced 79.88%	157,190 $1.37 Million
Q1 2022 May 13, 2022	BUY	$6.64 - $12.85 $291,110 - $563,369	43,842 Added 5.94%	781,388 $6.24 Million
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $1.57 Million - $2.09 Million	-145,500 Reduced 16.48%	737,546 $9.91 Million
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $7.62 Million - $10.2 Million	657,908 Added 292.22%	883,046 $11.5 Million
Q2 2021 Aug 16, 2021	SELL	$10.43 - $12.81 $312,900 - $384,300	-30,000 Reduced 11.76%	225,138 $2.61 Million
Q1 2021 May 17, 2021	SELL	$10.24 - $14.6 $3.92 Million - $5.59 Million	-382,956 Reduced 60.02%	255,138 $2.86 Million
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $5.57 Million - $9.67 Million	638,094 New	638,094 $6.77 Million

92.5M

313K

377K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $380M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.